Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $6.00

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned a consensus recommendation of “Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $6.1667.

A number of analysts have weighed in on IMUX shares. raised Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. D. Boral Capital dropped their target price on Immunic from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a research note on Monday, December 29th. HC Wainwright decreased their price target on Immunic from $8.00 to $5.00 and set a “buy” rating for the company in a report on Monday, March 2nd. Finally, Guggenheim started coverage on shares of Immunic in a research report on Tuesday, March 24th. They issued a “buy” rating and a $7.00 price objective on the stock.

Institutional Trading of Immunic

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Seven Fleet Capital Management LP acquired a new position in shares of Immunic during the fourth quarter worth about $83,000. Connective Capital Management LLC purchased a new position in Immunic during the fourth quarter worth about $161,000. XTX Topco Ltd acquired a new stake in Immunic in the fourth quarter valued at about $120,000. Millennium Management LLC boosted its holdings in Immunic by 544.6% in the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after purchasing an additional 2,888,829 shares in the last quarter. Finally, Laurion Capital Management LP boosted its holdings in Immunic by 106.3% in the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after purchasing an additional 2,000,000 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Stock Performance

Shares of NASDAQ:IMUX opened at $1.09 on Monday. The company has a 50-day simple moving average of $0.94 and a 200-day simple moving average of $0.81. Immunic has a one year low of $0.51 and a one year high of $1.51. The stock has a market capitalization of $142.21 million, a price-to-earnings ratio of -1.56 and a beta of 1.46.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). As a group, research analysts forecast that Immunic will post -0.94 EPS for the current fiscal year.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.